Q1 Earnings Forecast for DNLI Issued By William Blair

Denali Therapeutics Inc. (NASDAQ:DNLIFree Report) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Denali Therapeutics in a research note issued to investors on Monday, October 13th. William Blair analyst M. Minter anticipates that the company will earn ($0.86) per share for the quarter. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics’ Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.86) EPS and FY2028 earnings at ($0.49) EPS.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same period in the previous year, the firm earned ($0.59) EPS.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. TD Cowen upgraded Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. Finally, Morgan Stanley dropped their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $33.50.

Get Our Latest Research Report on Denali Therapeutics

Denali Therapeutics Trading Up 2.5%

Shares of DNLI stock opened at $16.72 on Thursday. The stock has a market capitalization of $2.44 billion, a PE ratio of -5.97 and a beta of 1.30. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The business has a 50-day moving average of $14.72 and a 200 day moving average of $14.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DNLI. Headlands Technologies LLC bought a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after acquiring an additional 1,551 shares in the last quarter. State of Wyoming bought a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Denali Therapeutics in the 1st quarter worth approximately $41,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,937 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares of the company’s stock, valued at $3,291,058.68. This represents a 1.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Carole Ho sold 2,937 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 217,391 shares of the company’s stock, valued at $2,952,169.78. The trade was a 1.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,680 shares of company stock valued at $91,569 in the last ninety days. 12.50% of the stock is currently owned by corporate insiders.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Read More

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.